Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
about
Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug developmentAlternative ways of modulating JAK-STAT pathway: Looking beyond phosphorylation.Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducinsA pepducin derived from the third intracellular loop of FPR2 is a partial agonist for direct activation of this receptor in neutrophils but a full agonist for cross-talk triggered reactivation of FPR2.Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide.Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor MimeticsCell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.Signal protein-derived peptides as functional probes and regulators of intracellular signaling.Strategic approaches to optimizing peptide ADME propertiesRegulation of the Melanocortin-Sensitive Adenylate Cyclase System by N-Acylated Peptide 71-82 of Type 4 Melanocortin Receptor.Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics.Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death.Palmitoylated peptide 562-572 of luteinizing hormone receptor increases testosterone level in male rats.
P2860
Q27024397-007D97AA-EE3F-4382-AC57-887AE5F5E73EQ34372827-90240852-B92D-4C6E-90C7-ECF0760605F4Q35002854-75389519-3D91-4A1E-8FE8-BF84A92DC90BQ35320697-1B0105B4-E816-48C7-A03F-E13CFD157C61Q35776992-DBAF4684-2A37-4265-A24B-0EA55CF0A40DQ35822572-6E09C550-0BA4-4861-9322-F979500F6C3FQ35860717-D4B764FB-BA49-475B-BC52-C4A854CF18B9Q36813106-FB164E79-30B1-4785-AF48-7B7B95DED15EQ37982071-ABCE3947-70FE-421C-B3A5-9CABB1F57BD6Q38264736-E390EAE5-A275-48F4-BCE4-A3D305A16358Q40290455-FFC1D271-7DE4-4970-AE9E-0CE92B9CE86FQ40405065-4C0535D0-7D74-405A-91D0-0C8988A752E0Q42066943-EDDF54AE-D755-43E2-849E-1DD76682DCBBQ43920446-DA6CF1CE-120F-4F2C-BCCF-FAD4A050E419
P2860
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@ast
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@en
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@nl
type
label
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@ast
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@en
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@nl
prefLabel
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@ast
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@en
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.
@nl
P2093
P2860
P1476
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models
@en
P2093
Athan Kuliopulos
Boris Tchernychev
Lidija Covic
Sarah L Tressel
Suzanne L Jacques
P2860
P304
P356
10.1007/978-1-60761-919-2_19
P407
P577
2011-01-01T00:00:00Z